There’s disappointing news about a potential Alzheimer’s drug.

Baxter International says a blood product it was testing failed to slow mental decline or to preserve physical function in a major study of 390 patients with mild to moderate Alzheimer’s disease.

Excitement about the drug, Gammagard, grew last summer, when researchers reported the drug had stabilized Alzheimer’s disease for as much as three years in four patients.